MONUMENT-RE-LIMITED
Monument Re announced today that it has completed the acquisition of the Charles Taylor Group’s Isle of Man life and investment operations, following receipt of regulatory approval from the Isle of Man Financial Services Authority and non-objection from the Bermuda Monetary Authority.
LCL International Life Assurance Company Limited has been renamed Monument International Life Assurance Company Limited and is the core life insurance entity in the Isle of Man.
About the Charles Taylor Group
Charles Taylor provides insurance services, claims and technology solutions to all parties within the global insurance market. Its technical expertise, technological tools and breadth of solutions enable its clients to outperform, by addressing complexities and challenges across every stage and aspect of the insurance lifecycle and operating model.
Charles Taylor employs approximately 3,100 staff in more than 120 locations spread across 30 countries in Europe, the Americas, Asia Pacific, the Middle East and Africa. It has earned the trust of a diversified, blue-chip international customer base that includes national and international insurance companies, mutuals, captives, MGAs, Lloyd's syndicates and reinsurers, along with brokers, distributors and corporate insureds.
About Monument Re
Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands, the Isle of Man and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset-intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios.
Monument Re is subject to Group Supervision by the Bermuda Monetary Authority.
To learn more, please visit www.monumentregroup.com or contact Fiona Davies at info@monumentregroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005120/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification18.12.2025 14:11:00 CET | Press release
Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/ Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities. This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula a
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release
Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom